Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC)[2].IC50 & Target:Kd: ~100 pM (CD20)In Vitro:AME-133v (0.027-20 μg/mL) concentration-dependently inhibits the binding of biotinylated Rituximab to CD20 in SKW6.4 cells.